Travere Therapeutics, Inc. $TVTX Stock: Russell Investments Group Ltd. Boosts Position

Russell Investments Group Ltd. boosted its position in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX – Free Report) by 96.6% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 778,340 shares of the company’s stock after purchasing an additional 382,371 shares during the quarter. Russell Investments Group Ltd.’s holdings in Travere Therapeutics were worth $45,829,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Jupiter Topco LLC purchased a new position in shares of Travere Therapeutics in the second quarter valued at $643,299,000. Bank of America Corp DE acquired a new position in shares of Travere Therapeutics during the 2nd quarter worth $259,527,000. Wellington Management Group LLP raised its stake in shares of Travere Therapeutics by 50.0% during the 2nd quarter. Wellington Management Group LLP now owns 1,533,080 shares of the company’s stock worth $87,094,000 after buying an additional 510,808 shares during the last quarter. Assenagon Asset Management S.A. raised its stake in shares of Travere Therapeutics by 168.1% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,145,414 shares of the company’s stock worth $67,442,000 after buying an additional 718,109 shares during the last quarter. Finally, Legal & General Group Plc purchased a new position in Travere Therapeutics during the 2nd quarter valued at about $26,723,000.

Analysts Set New Price Targets

TVTX has been the subject of a number of research reports. JPMorgan Chase & Co. cut their target price on shares of Travere Therapeutics from $90.00 to $86.00 and set an “overweight” rating for the company in a research report on Friday, November 6th. TD Cowen upped their price target on shares of Travere Therapeutics from $60.00 to $75.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Leerink Partners lowered their price target on shares of Travere Therapeutics from $78.00 to $67.00 and set an “outperform” rating on the stock in a research report on Thursday, November 5th. Evercore set a $78.00 price objective on shares of Travere Therapeutics in a research note on Monday, August 10th. Finally, Guggenheim cut their price objective on Travere Therapeutics from $89.00 to $78.00 and set a “buy” rating for the company in a research report on Wednesday, November 4th. Eleven analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $72.55.

Get Our Latest Stock Report on Travere Therapeutics

Insider Transactions at Travere Therapeutics

In related news, CFO Christopher Cline sold 50,508 shares of the stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $62.34, for a total transaction of $3,148,668.72. Following the transaction, the chief financial officer directly owned 87,508 shares in the company, valued at approximately $5,455,248.72. This represents a 36.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jula Inrig sold 44,674 shares of the stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $62.34, for a total value of $2,784,977.16. Following the transaction, the executive vice president owned 100,491 shares in the company, valued at $6,264,608.94. This trade represents a 30.77% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 1,294,029 shares of company stock valued at $79,454,261. Corporate insiders own 4.44% of the company’s stock.

Travere Therapeutics Stock Performance

Shares of TVTX opened at $50.65 on Monday. Travere Therapeutics, Inc. has a fifty-two week low of $22.59 and a fifty-two week high of $68.73. The company has a market capitalization of $4.86 billion, a PE ratio of -39.26 and a beta of 1.11. The stock has a fifty day moving average of $55.93 and a two-hundred day moving average of $47.55. The company has a debt-to-equity ratio of 26.72, a quick ratio of 2.95 and a current ratio of 3.00.

Travere Therapeutics (NASDAQ:TVTX – Get Free Report) last posted its quarterly earnings data on Monday, November 2nd. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.49). Travere Therapeutics had a negative return on equity of 185.69% and a negative net margin of 18.66%. The business had revenue of $224.56 million for the quarter, compared to analyst estimates of $195.29 million. During the same quarter last year, the business earned $0.28 EPS. Travere Therapeutics’s revenue for the quarter was up 36.2% compared to the same quarter last year. As a group, analysts forecast that Travere Therapeutics, Inc. will post -0.90 EPS for the current year.

About Travere Therapeutics

(Free Report)

Travere Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases, with an emphasis on kidney and metabolic disorders. The company was formerly known as Retrophin and adopted the Travere Therapeutics name in 2020. Its commercial products include FILSPARI (sparsentan), an oral treatment approved in the United States for adults with primary IgA nephropathy at risk of disease progression, and THIOLA EC (tiopronin), used to help prevent cystine kidney stones in people with cystinuria.

Featured Articles

Want to see what other hedge funds are holding TVTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Travere Therapeutics, Inc. (NASDAQ:TVTX – Free Report).

Institutional Ownership by Quarter for Travere Therapeutics (NASDAQ:TVTX)

Receive News & Ratings for Travere Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Travere Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.